Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1. 
Via Benzinga
Catalent, Inc. Reports Second Quarter Fiscal 2022 Results
From Catalent, Inc.
Via Business Wire
A Bearish Sign Appears On Catalent's Chart
If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter: 
Via Benzinga
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within ... 
Via Benzinga
Where Catalent Stands With Analysts
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within ... 
Via Benzinga
Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change. 
Via Investor's Business Daily
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for... 
Via Benzinga
Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022
From Catalent, Inc.
Via Business Wire
Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Catalent, Inc.
Via Business Wire
A Look Into Catalent's Price Over Earnings
In the current session, Catalent Inc. (NYSE:CTLT) is trading at $128.13, after a 0.1% increase. Over the past month, the stock increased by 0.34%, and in the past... 
Via Benzinga
Catalent, Inc. to Present at the Stephens Annual Investment Conference
From Catalent, Inc.
Via Business Wire
Catalent, inc (CTLT) Q1 2022 Earnings Call Transcript
CTLT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: 
Via Benzinga
Catalent, Inc. Reports First Quarter Fiscal 2022 Results
From Catalent, Inc.
Via Business Wire
Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
Chair And CEO Of Catalent Trades $22M In Company Stock
John Chiminski, Chair And CEO at Catalent (NYSE:CTLT), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030
From Catalent, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030
From Catalent, Inc.
Via Business Wire
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From Catalent, Inc.
Via Business Wire
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
Market Rally At Highs, Led By Apple, Growth Stocks: Weekly Review
The market rally hit fresh highs this week, with growth leading the way. 
Via Investor's Business Daily
Topics Bonds Economy Stocks
Exposures Debt Markets Fossil Fuels Interest Rates
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.